MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

SAGE Therapeutics Company Profile (NASDAQ:SAGE)

Consensus Ratings for SAGE Therapeutics (NASDAQ:SAGE) (?)
Ratings Breakdown: 1 Sell Rating(s), 9 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $67.50 (124.03% upside)

Analysts' Ratings History for SAGE Therapeutics (NASDAQ:SAGE)
Show:
DateFirmActionRatingPrice TargetActions
6/28/2016BMO Capital MarketsInitiated CoverageOutperform$48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/23/2016HC WainwrightInitiated CoverageBuy$56.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/21/2016Leerink SwannReiterated RatingOutperform$66.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Chardan CapitalReiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2016Goldman SachsReiterated RatingBuy$63.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/27/2016William BlairReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2016Lake Street CapitalInitiated CoverageBuy$90.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2015SunTrustInitiated CoverageBuy$67.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/1/2014 forward)
Earnings History for SAGE Therapeutics (NASDAQ:SAGE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/5/2016Q1($0.98)($0.97)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2016Q4($0.94)($0.99)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.68)($0.90)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q115($0.56)($0.66)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2015Q414($0.44)($1.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2014Q314($0.40)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2014Q214($1.23)($4.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for SAGE Therapeutics (NASDAQ:SAGE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.99)($0.91)($0.95)
Q2 20164($1.12)($0.94)($1.01)
Q3 20164($1.22)($0.94)($1.06)
Q4 20164($1.29)($0.93)($1.09)
(Data provided by Zacks Investment Research)
Dividend History for SAGE Therapeutics (NASDAQ:SAGE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for SAGE Therapeutics (NASDAQ:SAGE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/16/2016Kevin P StarrDirectorSell850,000$31.25$26,562,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/19/2016Stephen KanesInsiderSell21,000$38.00$798,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/25/2016Albert RobichaudInsiderSell20,000$40.02$800,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/28/2015Stephen KanesinsiderSell6,000$46.42$278,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Kimi IguchiCFOSell3,000$54.84$164,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Steven M. PaulDirectorSell20,000$52.41$1,048,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/31/2015Stephen KanesInsiderSell12,000$53.12$637,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2015Jeffrey M JonasInsiderSell3,000$76.79$230,370.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Kimi IguchiCFOSell4,000$68.00$272,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Albert RobichaudInsiderSell16,000$72.13$1,154,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Steven M PaulDirectorSell20,000$69.40$1,388,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2015Stephen KanesInsiderSell6,000$74.06$444,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015Jeffrey M JonasInsiderSell198,600$77.36$15,363,696.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Thomas AndersonInsiderSell5,500$79.65$438,075.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Albert RobichaudInsiderSell16,000$72.80$1,164,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Steven M PaulDirectorSell20,000$72.34$1,446,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2015Stephen KanesInsiderSell6,000$42.05$252,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015Stephen KanesInsiderSell6,000$37.29$223,740.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2014James M FratesDirectorBuy5,000$18.00$90,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2014Stephen KanesInsiderBuy3,000$18.00$54,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for SAGE Therapeutics (NASDAQ:SAGE)
DateHeadline
06/30/16 06:29 PMH.C. Wainwright Initiates Coverage on SAGE Therapeutics Inc to Buy - Trade Calls
06/30/16 09:03 AMIs Sage Therapeutics (NASDAQ:SAGE) Worth Your Time? BMO Capital Thinks So - Press Telegraph
06/28/16 06:08 PMOption Market: Sage Therapeutics Inc. Risk Hits An Extreme High - CML News
06/28/16 11:03 AMSAGE Therapeutics : Why Investors Have These Biotech Stocks on Their Radar? - Cerus, Juno Therapeutics, Chiasma, and Sage Therapeutics
06/27/16 10:25 AMHot Stock List: Sage Therapeutics, Inc. (NASDAQ:SAGE), Cracker Barrel Old Country Store, Inc. (NASDAQ:CBRL ... - KC Register
06/27/16 10:25 AMNext Weeks Broker Price Targets For Sage Therapeutics, Inc. (SAGE) - Fiscal Standard
06/25/16 09:59 AMSage Therapeutics (NASDAQ:SAGE) stock price target bumped up to $56 as recorded today by H.C. Wainwright
06/24/16 09:01 AMBulls see upside in Sage Therapeutics -
06/24/16 08:51 AMBlackBerry CEO confident on handset profit; results top expectations
06/23/16 03:10 PMSAGE THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/15/16 06:10 PMAnalysts Offer Insights on Healthcare Companies: SAGE Therapeutics Inc (NASDAQ: SAGE) and Adamas ... - Markets.co
06/13/16 09:10 AMTrading updates about two Stocks: Kite Pharma, Inc. (NASDAQ:KITE) , Sage Therapeutics, Inc. (NASDAQ:SAGE) - Street Updates
06/08/16 06:45 PMSAGE Therapeutics Received its Third Buy in a Row - Analyst Ratings
06/08/16 06:45 PMSAGE THERAPEUTICS INC. (NASDAQ:SAGE) Financial Condition Compared to S&P 500 - CML News
06/07/16 03:28 PMSage Reports Positive Top-line Results from Phase 1 Clinical Program of SAGE-217 - [at noodls] - SAGE-217 was well-tolerated in single and multiple ascending doses Results consistent with predicted pharmacokinetic and pharmacologic profile Initiation of Phase 2 clinical trials planned for second half ...
06/04/16 09:14 AMSummary of Analysts Rating: Quintiles Transitional Holdings Inc. (NYSE:Q) , Sage Therapeutics, Inc. (NASDAQ:SAGE) - Street Updates
06/02/16 09:20 AMSage Therapeutics, Inc. (SAGE) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Sage Therapeutics, Inc. (SAGE) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Sage Therapeutics, Inc. (SAGE). The latest reports which are currently in issue on Thursday 2nd of June state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, ...and more »
06/01/16 06:51 PMSage Therapeutics to Present at the Goldman Sachs 37th Annual Global Healthcare Conference - Business Wire (press release) - Sage Therapeutics to Present at the Goldman Sachs 37th Annual Global Healthcare ConferenceBusiness Wire (press release)CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.D., ...
06/01/16 04:00 PMSAGE Therapeutics, Inc. :SAGE-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
06/01/16 03:45 PMSage Therapeutics to Present at the Goldman Sachs 37th Annual Global Healthcare Conference - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, ...
06/01/16 09:10 AMChardan Capital Initiates Coverage on SAGE Therapeutics Inc to Sell - Trade Calls - Chardan Capital Initiates Coverage on SAGE Therapeutics Inc to SellTrade CallsChardan Capital Initiates Coverage on SAGE Therapeutics Inc(NASDAQ:SAGE). The shares have been rated Sell. The rating by Chardan Capital was issued on May 24, 2016. In a different note, Goldman Sachs said it Initiates Coverage on SAGE ...and more »
05/31/16 03:08 PMSAGE THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhi -
05/31/16 10:25 AMStock Review and Earnings Check on Sage Therapeutics, Inc. (NASDAQ:SAGE) - HNN - Stock Review and Earnings Check on Sage Therapeutics, Inc. (NASDAQ:SAGE)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Sage Therapeutics, Inc.and more »
05/30/16 12:54 PMSAGE Therapeutics (SAGE) – Analysts' Recent Ratings Changes - Let Me Know About This - SAGE Therapeutics (SAGE) – Analysts' Recent Ratings ChangesLet Me Know About ThisShares of SAGE Therapeutics Inc (NASDAQ:SAGE) opened at 31.48 on Monday. The stock's market cap is $1.01 billion. The firm has a 50-day moving average of $34.99 and a 200 day moving average of $39.46. SAGE Therapeutics Inc has a 52 week low of ...
05/29/16 11:41 AMAnalysts Offer Insights on Healthcare Companies: SAGE Therapeutics Inc (NASDAQ: SAGE), T2 Biosystems (NASDAQ ... - Analyst Ratings - Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics Inc (NASDAQ: SAGE), T2 Biosystems (NASDAQ ...Analyst RatingsThere's a lot to be optimistic about in the Healthcare sector as 2 experts just weighed in on SAGE Therapeutics Inc (NASDAQ: SAGE), T2 Biosystems (NASDAQ: TTOO) and Seres Therapeutics Inc. (NASDAQ: MCRB) with bullish sentimens.and more »
05/27/16 11:59 AMBRIEF-Sage Therapeutics says completed enrollment for Phase 2 trial of Sage-547 - Reuters - ReutersBRIEF-Sage Therapeutics says completed enrollment for Phase 2 trial of Sage-547ReutersMay 26 Sage Therapeutics Inc. * SAGE THERAPEUTICS announces completion of enrollment for phase 2 proof-of-concept trial of sage-547 in severe postpartum depression Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 ...
05/27/16 11:59 AMSage Therapeutics Announces Completion of Enrollment for Phase 2 Proof-of-Concept Trial of SAGE-547 in Severe ... - Business Wire (press release) - TheStreet.comSage Therapeutics Announces Completion of Enrollment for Phase 2 Proof-of-Concept Trial of SAGE-547 in Severe ...Business Wire (press release)CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that enrollment has ...Sage Therapeutics Completes Enrollment in Phase 2 Trial of SAGE-547 in Severe Postpartum Depression (NASDAQ ...Sonoran Weekly ReviewBiotech Stock Mailbag: Sage Therapeutics, MinervaTheStreet.comSAGE Therapeutics completes enrollment in mid-stage study of lead product candidate in postpartum depressionSeeking Alphaall 4 news articles »
05/27/16 06:00 AMBiotech Stock Mailbag: Sage Therapeutics, Minerva -
05/26/16 03:17 PMSage Therapeutics Announces Completion of Enrollment for Phase 2 Proof-of-Concept Trial of SAGE-547 in Severe Postpartum Depression - [at noodls] - Full top-line dataset, including 30-day follow-up, expected in July 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing ...
05/26/16 03:09 PM4:09 pm SAGE Therapeutics completes enrollment in Phasw 2 clinical trial of SAGE-547 in women with severe postpartum depression -
05/26/16 11:05 AMChardan Expecting Nearly 50% Downside In Sage Therapeutics, Starts At Sell - Benzinga - Chardan Expecting Nearly 50% Downside In Sage Therapeutics, Starts At SellBenzingaSAGE Therapeutics Inc SAGE is expected to announce Phase 3 data for its lead candidate SAGE-547 [allopregnanolone] in super-refractory status epilepticus [SRSE] in 2H16. Chardan Capital Markets' Gbola Amusa initiated coverage of the company with a ...Chardan Capital Starts Sage Therapeutics With Sell Rating, $18 PT; Shares Down 10% (NASDAQ:SAGE)Sonoran Weekly ReviewCould SAGE Therapeutics Inc Decline After Today's Huge Increase?Franklin IndependentSAGE Therapeutics Inc (SAGE) Earns Sell Rating from Analysts at Chardan CapitalCommunity Financial NewsMarket Digest -Wall Street Hints and News -FTSE Newsall 10 news articles »
05/26/16 11:05 AMCormorant Asset Management LLC Increased Sage Therapeutics INC (NASDAQ:SAGE) by $20.16 Million as Shares ... - CCH Daily News - Cormorant Asset Management LLC Increased Sage Therapeutics INC (NASDAQ:SAGE) by $20.16 Million as Shares ...CCH Daily NewsCormorant Asset Management Llc increased its stake in Sage Therapeutics Inc (NASDAQ:SAGE) by 200% based on its latest 2016Q1 regulatory filing with the SEC. Cormorant Asset Management Llc bought 630,000 shares as the company's stock declined ...and more »
05/24/16 05:25 AMCoverage initiated on SAGE Therapeutics by Chardan Capital Markets -
05/06/16 04:00 PMSAGE THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report -
05/05/16 04:11 PMSage Therapeutics reports 1Q loss -
05/05/16 03:44 PMSage Therapeutics Announces First Quarter 2016 Financial Results - [at noodls] - Five data presentations across two indications presented at AAN Annual Meeting Multiple upcoming milestones and events planned for 2016 Conference call today at 4:30 PM ET CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ...
05/05/16 03:30 PMSAGE Therapeutics Inc Earnings Call scheduled for 4:30 pm ET today -
05/05/16 06:07 AMQ1 2016 SAGE Therapeutics Inc Earnings Release - Before Market Open -
05/03/16 03:05 PMSAGE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib -
04/28/16 03:15 PMSage Therapeutics to Report First Quarter 2016 Financial Results on Thursday, May 5, 2016 - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, ...
04/17/16 03:46 PMSage Therapeutics Expands Scientific, Clinical and Burden of Illness Data for SAGE-547 in SRSE and Essential Tremor at the 2016 American Academy of Neurology Annual Meeting - [at noodls] - SAGE-547 response rate in SRSE Phase 1/2 trial not impacted by patient characteristics Potential pharmacodynamic biomarker identified for SAGE-547 informs STATUS Trial protocol Analyses from hospital chargemaster ...
04/14/16 04:49 PMThree names to focus on in biotech -
02/26/16 11:48 AMChanges To Broker Targets On Sage Therapeutics, Inc. (SAGE) - Share Trading News - Changes To Broker Targets On Sage Therapeutics, Inc. (SAGE)Share Trading News02/25/2016 – Sage Therapeutics, Inc. had its “outperform” rating reiterated by analysts at William Blair. They now have a USD 58 price target on the stock. 12/15/2015 – Sage Therapeutics, Inc. had its “buy” rating reiterated by analysts at Canaccord ...
02/24/16 03:24 PMSAGE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E -
02/24/16 12:56 PMEdited Transcript of SAGE earnings conference call or presentation 24-Feb-16 1:30pm GMT -
02/24/16 07:30 AMSAGE Therapeutics Inc Earnings Call scheduled for 8:30 am ET today -
02/24/16 07:01 AMSage Therapeutics reports 4Q loss -
02/24/16 06:00 AMSage Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results - [GlobeNewswire] - Top-line Results of Phase 3 STATUS Trial for SAGE-547 in SRSE Expected in 2 H 2016. Robust, Wholly-Owned Pipeline Includes 6 Novel Compounds in Evaluation across Multiple CNS Indications. 3 Clinical Data ...
02/17/16 03:05 PMSage Therapeutics to Report Fourth Quarter and Full Year 2015 Financial Results on Wednesday, February 24, 2016 - [GlobeNewswire] - CAMBRIDGE, Mass., Feb. 17, 2016-- Sage Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that ...
02/11/16 01:32 PM13G Filing: Visium Asset Management and Sage Therapeutics, Inc. (SAGE) -
About SAGE Therapeutics

SAGE Therapeutics logoSAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening, rare central nervous system (CNS) disorders. The Company's lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline. The Company has submitted investigational new drug (IND) for SAGE-547 for the treatment of SRSE with the United States Food and Drug Administration. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. SAGE-217 is a neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes. SAGE-689 is being developed as an adjunctive IV therapy for the treatment of status epilepticus patients.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SAGE
  • CUSIP:
Key Metrics:
  • Previous Close: $30.13
  • 50 Day Moving Average: $31.02
  • 200 Day Moving Average: $36.56
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $966.06M
  • Current Quarter EPS Consensus Estimate: $-4.26 EPS
Additional Links:
SAGE Therapeutics (NASDAQ:SAGE) Chart for Friday, July, 1, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha